Candida auris is identified as an emerging pathogen worldwide. It is multidrug resistant and causes invasive healthcare-associated infections. Our retrospective study was conducted to determine the prevalence and epidemiology of C. auris infections in a tertiary care hospital in Jaipur.
24 clinical C. auris strains were included, most being from urine. The majority patients needed intensive care and had at least one underlying co-morbid condition. A history of broad-spectrum antibiotic or antifungal usage was present in 85%. Fluconazole, voriconazole, amphotericin B and 5-fluorocytosine resistance was seen in 96, 42, 33 and 8% isolates respectively. No echinocandin resistance was noted.
CortegianiAMisseriGFascianaT, et al.Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care2018; 6: 69–69.
4.
SatohKMakimuraKHasumiY, et al.Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol2009; 53: 41–44.
5.
ChowdharyASharmaA. The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic. J Glob Antimicrob Resist2020; 22: 175–176.
6.
NettJE. Candida auris: an emerging pathogen “incognito”?PLoS Pathog2019; 15: 1–6.
7.
ICMR. Candida auris in healthcare settings – India. New Delhi, India: Indian Council of Medical Research, 2017, pp.1–5.
8.
HospenthalDRMurrayCKBeckiusML, et al.Persistence of pigment production by yeast isolates grown on CHROMagar Candida medium. J Clin Microbiol2002; 40: 4768–4770.
9.
Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Approved Standard M27-A3. Wayne, PA: CLSI, 2008.
10.
AroraPSinghPWangY, et al.Environmental isolation of Candida auris from the coastal wetlands of Andaman Islands, India. mBio2021; 12: e03181–e03120.
